Literature DB >> 23526455

RNA sequencing of MCF-7 breast cancer cells identifies novel estrogen-responsive genes with functional estrogen receptor-binding sites in the vicinity of their transcription start sites.

Ryonosuke Yamaga1, Kazuhiro Ikeda, Kuniko Horie-Inoue, Yasuyoshi Ouchi, Yutaka Suzuki, Satoshi Inoue.   

Abstract

Estrogen receptor α (ERα) is a key transcription factor in breast cancer, which plays an essential role in the pathophysiology of the disease by regulating the expression of various target genes. In the present study, we performed deep RNA sequencing (RNA-seq) as an unbiased high-throughput technique for comprehensive transcriptome analysis in ERα-positive human breast cancer MCF-7 cells, to facilitate the elucidation of ERα regulatory gene networks. From the 17,336 mapped RefSeq genes from the sequenced fragments of the cell samples treated with estrogen time dependently, substantial numbers of sequence reads were observed in 3,386 genes (>100 tags per million reads per sample at any of the six time points studied). ERα occupancy within and in the proximal regions of the genes (<10-kb upstream and downstream regions) was significantly enriched in the subgroup of the 3,386 genes compared to the whole 17,336 RefSeq genes. Of the 3,386 genes, we focused on 29 genes, which included ERα occupancy adjacent to their transcription start sites and whose expression was estrogen dependently altered by >3-fold. Knockdown studies using siRNAs specific to the 29 genes validated that prototypic ERα targets V-myc myelocytomatosis viral oncogene homolog and cyclin D1 promote both proliferation and migration of MCF-7 cells and further identified novel candidate ERα targets EIF3A and tumor protein D52-like 1, which will also facilitate the proliferation or migration of MCF-7 cells. Taken together, the present findings provide a valuable dataset that will elucidate ERα regulatory mechanisms in breast cancer biology, based on the integrative analysis of RNA-seq combined with the genome-wide information for ERα occupancy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23526455     DOI: 10.1007/s12672-013-0140-3

Source DB:  PubMed          Journal:  Horm Cancer        ISSN: 1868-8497            Impact factor:   3.869


  41 in total

1.  D53 (TPD52L1) is a cell cycle-regulated protein maximally expressed at the G2-M transition in breast cancer cells.

Authors:  Rose Boutros; Jennifer A Byrne
Journal:  Exp Cell Res       Date:  2005-10-15       Impact factor: 3.905

2.  Transcriptional regulation of the human NRIP1/RIP140 gene by estrogen is modulated by dioxin signalling.

Authors:  Patrick Augereau; Eric Badia; Maryse Fuentes; Fanja Rabenoelina; Marine Corniou; Danièle Derocq; Patrick Balaguer; Vincent Cavailles
Journal:  Mol Pharmacol       Date:  2006-01-03       Impact factor: 4.436

3.  Genome-wide analysis of estrogen receptor binding sites.

Authors:  Jason S Carroll; Clifford A Meyer; Jun Song; Wei Li; Timothy R Geistlinger; Jérôme Eeckhoute; Alexander S Brodsky; Erika Krasnickas Keeton; Kirsten C Fertuck; Giles F Hall; Qianben Wang; Stefan Bekiranov; Victor Sementchenko; Edward A Fox; Pamela A Silver; Thomas R Gingeras; X Shirley Liu; Myles Brown
Journal:  Nat Genet       Date:  2006-10-01       Impact factor: 38.330

4.  Role of eIF3a in regulating cell cycle progression.

Authors:  Zizheng Dong; Zhaoqian Liu; Ping Cui; Roxana Pincheira; Youyun Yang; Jianguo Liu; Jian-Ting Zhang
Journal:  Exp Cell Res       Date:  2009-03-24       Impact factor: 3.905

5.  Effect of the secretory small GTPase Rab27B on breast cancer growth, invasion, and metastasis.

Authors:  An Hendrix; Dawn Maynard; Patrick Pauwels; Geert Braems; Hannelore Denys; Rudy Van den Broecke; Jo Lambert; Simon Van Belle; Veronique Cocquyt; Christian Gespach; Marc Bracke; Miguel C Seabra; William A Gahl; Olivier De Wever; Wendy Westbroek
Journal:  J Natl Cancer Inst       Date:  2010-05-18       Impact factor: 13.506

6.  Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer.

Authors:  Toula Bouras; Melissa C Southey; Andy C Chang; Roger R Reddel; Dorian Willhite; Richard Glynne; Michael A Henderson; Jane E Armes; Deon J Venter
Journal:  Cancer Res       Date:  2002-03-01       Impact factor: 12.701

7.  Transcription factor EGR3 is involved in the estrogen-signaling pathway in breast cancer cells.

Authors:  A Inoue; Y Omoto; Y Yamaguchi; R Kiyama; S-I Hayashi
Journal:  J Mol Endocrinol       Date:  2004-06       Impact factor: 5.098

8.  Variation in genes required for normal mitosis and risk of breast cancer.

Authors:  J E Olson; X Wang; E L Goode; V S Pankratz; Z S Fredericksen; R A Vierkant; P D P Pharoah; J R Cerhan; F J Couch
Journal:  Breast Cancer Res Treat       Date:  2009-04-18       Impact factor: 4.872

9.  Regulation of GREB1 transcription by estrogen receptor alpha through a multipartite enhancer spread over 20 kb of upstream flanking sequences.

Authors:  Julie Deschênes; Véronique Bourdeau; John H White; Sylvie Mader
Journal:  J Biol Chem       Date:  2007-04-26       Impact factor: 5.157

10.  Tumor suppressor function of Rab25 in triple-negative breast cancer.

Authors:  Ji-Ming Cheng; Lisa Volk; Deepak Kumar Mummidavarapu Janaki; Sudhir Vyakaranam; Sophia Ran; Krishna A Rao
Journal:  Int J Cancer       Date:  2010-06-15       Impact factor: 7.396

View more
  19 in total

Review 1.  Identification of estrogen-responsive genes based on the DNA binding properties of estrogen receptors using high-throughput sequencing technology.

Authors:  Kazuhiro Ikeda; Kuniko Horie-Inoue; Satoshi Inoue
Journal:  Acta Pharmacol Sin       Date:  2014-12-15       Impact factor: 6.150

Review 2.  RET revisited: expanding the oncogenic portfolio.

Authors:  Lois M Mulligan
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

3.  Single-Molecule Sequencing Reveals Estrogen-Regulated Clinically Relevant lncRNAs in Breast Cancer.

Authors:  Philip Jonsson; Cristian Coarfa; Fahmi Mesmar; Tal Raz; Kimal Rajapakshe; John F Thompson; Preethi H Gunaratne; Cecilia Williams
Journal:  Mol Endocrinol       Date:  2015-10-01

Review 4.  Hormone-regulated transcriptomes: lessons learned from estrogen signaling pathways in breast cancer cells.

Authors:  Nasun Hah; W Lee Kraus
Journal:  Mol Cell Endocrinol       Date:  2013-06-28       Impact factor: 4.102

5.  BQ323636.1, a Novel Splice Variant to NCOR2, as a Predictor for Tamoxifen-Resistant Breast Cancer.

Authors:  Chun Gong; Ellen P S Man; Ho Tsoi; Terence K W Lee; Paul Lee; Sai-Ting Ma; Lai-San Wong; Mai-Yee Luk; Emad A Rakha; Andrew R Green; Ian O Ellis; Eric W-F Lam; Kwok-Leung Cheung; Ui-Soon Khoo
Journal:  Clin Cancer Res       Date:  2018-02-02       Impact factor: 12.531

6.  Extracellular Matrix-Bound FGF2 Mediates Estrogen Receptor Signaling and Therapeutic Response in Breast Cancer.

Authors:  Josh W DiGiacomo; Inês Godet; Michael Trautmann-Rodriguez; Daniele M Gilkes
Journal:  Mol Cancer Res       Date:  2020-10-08       Impact factor: 6.333

7.  Circulating mRNA Profiling in Esophageal Squamous Cell Carcinoma Identifies FAM84B As A Biomarker In Predicting Pathological Response to Neoadjuvant Chemoradiation.

Authors:  Feng-Ming Hsu; Jason Chia-Hsien Cheng; Yih-Leong Chang; Jang-Ming Lee; Albert C Koong; Eric Y Chuang
Journal:  Sci Rep       Date:  2015-05-18       Impact factor: 4.379

Review 8.  The emerging role of RNA N6-methyladenosine methylation in breast cancer.

Authors:  Fangchao Zheng; Feng Du; Jiuda Zhao; Xue Wang; Yiran Si; Peng Jin; Haili Qian; Binghe Xu; Peng Yuan
Journal:  Biomark Res       Date:  2021-05-27

9.  Short hairpin RNA library-based functional screening identified ribosomal protein L31 that modulates prostate cancer cell growth via p53 pathway.

Authors:  Yojiro Maruyama; Toshiaki Miyazaki; Kazuhiro Ikeda; Toshiyuki Okumura; Wataru Sato; Kuniko Horie-Inoue; Koji Okamoto; Satoru Takeda; Satoshi Inoue
Journal:  PLoS One       Date:  2014-10-06       Impact factor: 3.240

10.  eIF3a improve cisplatin sensitivity in ovarian cancer by regulating XPC and p27Kip1 translation.

Authors:  Yu Zhang; Jing-Jing Yu; Yan Tian; Zheng-Zheng Li; Cai-Yi Zhang; Shu-Fen Zhang; Lan-Qin Cao; Yi Zhang; Chen-Yue Qian; Wei Zhang; Hong-Hao Zhou; Ji-Ye Yin; Zhao-Qian Liu
Journal:  Oncotarget       Date:  2015-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.